Zeleciment rostudirsen (z-rostudirsen)

Name: Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: Mechanism of action
Published: 2026-09-14T15:39:06-04:00

Duchenne muscular dystrophy

Also known as DYNE-251

Manufacturer: Dyne Therapeutics
Regulatory submission: BLA submitted May 2026
Launch: Anticipated in the first quarter of 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information Pharmacology

Mechanism of action

1 evidence topic · 1 source

Exon-skipping mechanism

“restore the open reading frame of the DMD transcript and enable the translation of a shortened but functional dystrophin protein” (opens the source at this quote in a new tab)